Huong D. Nguyen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Huong D. Nguyen has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Lucy R. Wedderburn
University College London Great Ormond Street Institute of Child Health, London, UK
5 shared publications - Adam P. Croft
Rheumatology Research Group, Department of Inflammation and Ageing, College of Medicine & Health, University of Birmingham, Birmingham, UK
3 shared publications - Charalampia Papadopoulou
Paediatric Rheumatology, Great Ormond Street Hospital for Children, NHS Foundation Trust , London
3 shared publications - Christopher Mahony
Rheumatology Research Group, Department of Inflammation and Ageing, College of Medicine & Health, University of Birmingham, Birmingham, UK
3 shared publications - Francesca Di Cara
Dalhousie University, Department of Microbiology and Immunology
3 shared publications - Andrew W. Stadnyk
Department of Microbiology and Immunology, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada
2 shared publications
Latest Publications
- Open Access
- 9 August 2025
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 84 (10) , 1706-1720
Spatial transcriptomic analysis of muscle biopsy from patients with treatment-naive juvenile dermatomyositis reveals mitochondrial abnormalities despite disease-related interferon-driven signature
- 9 August 2025
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 84 (10) , 1706-1720
Open AccessSpatial transcriptomic analysis of muscle biopsy from patients with treatment-naive juvenile dermatomyositis reveals mitochondrial abnormalities despite disease-related interferon-driven signature
- Top Cited PapersOpen Access
- 2 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (805) , eadt6050
Synovial tissue atlas in juvenile idiopathic arthritis reveals pathogenic niches associated with disease severity
Precision application of targeted therapies is urgently needed to improve long-term clinical outcomes for children affected by inflammatory arthritis, known as juvenile idiopathic arthritis (JIA). Progress has been hampered by our limited understanding of the cellular basis of inflammation in the target tissue of the disease, the synovial membrane. Here, we analyzed biopsies from the inflamed joints of treatment-naïve children with JIA, early in the course of their disease, using single-cell RNA sequencing, multiplexed immunofluorescence, and spatial transcriptomics to establish a cellular atlas of the JIA synovium. We identified distinct spatial tissue niches, composed of specific stromal and immune cell populations. In addition, we localized genes linked to arthritis severity and disease risk to effector cell populations, including tissue resident SPP1 + macrophages and fibrin-associated myeloid cells. Combined analyses of synovial fluid and peripheral blood from matched individuals revealed differences in cellular composition, signaling pathways, and transcriptional programs across these distinct anatomical compartments. Furthermore, our analysis revealed several pathogenic cell populations that are shared with adult-onset inflammatory arthritis, as well as age-associated differences in tissue vascularity, prominence of innate immunity, and enrichment of TGF-β–responsive stromal subsets that up-regulate expression of disease risk–associated genes. Overall, our findings demonstrate the need for age-specific analyses of synovial tissue pathology to guide targeted treatment strategies in JIA.
- 2 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (805) , eadt6050
Top Cited PapersOpen AccessSynovial tissue atlas in juvenile idiopathic arthritis reveals pathogenic niches associated with disease severity
Precision application of targeted therapies is urgently needed to improve long-term clinical outcomes for children affected by inflammatory arthritis, known as juvenile idiopathic arthritis (JIA). Progress has been hampered by our limited understanding of the cellular basis of inflammation in the target tissue of the disease, the synovial membrane. Here, we analyzed biopsies from the inflamed joints of treatment-naïve children with JIA, early in the course of their disease, using single-cell RNA sequencing, multiplexed immunofluorescence, and spatial transcriptomics to establish a cellular atlas of the JIA synovium. We identified distinct spatial tissue niches, composed of specific stromal and immune cell populations. In addition, we localized genes linked to arthritis severity and disease risk to effector cell populations, including tissue resident SPP1 + macrophages and fibrin-associated myeloid cells. Combined analyses of synovial fluid and peripheral blood from matched individuals revealed differences in cellular composition, signaling pathways, and transcriptional programs across these distinct anatomical compartments. Furthermore, our analysis revealed several pathogenic cell populations that are shared with adult-onset inflammatory arthritis, as well as age-associated differences in tissue vascularity, prominence of innate immunity, and enrichment of TGF-β–responsive stromal subsets that up-regulate expression of disease risk–associated genes. Overall, our findings demonstrate the need for age-specific analyses of synovial tissue pathology to guide targeted treatment strategies in JIA.
- Open Access
Spatial transcriptomic analysis of muscle biopsy from treatment-naive juvenile dermatomyositis patients reveals mitochondrial abnormalities despite disease-related interferon driven signature
Objectives: This study aimed to investigate the spatial transcriptomic landscape of muscle tissue from treatment-naïve juvenile dermatomyositis (JDM) patients in comparison to healthy paediatric muscle tissue. Methods: Muscle biopsies from three JDM patients and three age-matched controls were analysed using the Nanostring GeoMx® Digital Spatial Profiler. Regions of interest were selected based on muscle fibres without immune cells, immune cell infiltration and CD68+ macrophage enrichment. Differential gene expression, pathway analysis and pathways clustering analysis were conducted. Key findings were validated in 19 cases of JDM using immunohistochemistry and chemical stains, and a bulk RNAseq dataset of four cases of JDM. Results: JDM muscle tissues exhibited significant interferon pathway activation and mitochondrial dysfunction compared to controls. A 15-gene interferon signature was significantly elevated in JDM muscle and macrophage-enriched regions, correlating with clinical weakness. In contrast, mitochondrial dysregulation, characterized by downregulated respiratory chain pathways, was present regardless of interferon activity or muscle strength. The interferon-driven and mitochondrial signatures were replicated in an independent RNAseq dataset from JDM muscle; lack of association between interferon signature and mitochondrial dysregulation was validated in 19 cases by conventional staining methods. Clustering analysis revealed distinct transcriptomic profiles between JDM and control tissues, as well as between JDM patients with varying clinical phenotypes. Conclusions: This study highlights mitochondrial dysfunction as a consistent pathological feature in JDM muscle, which may be independent of interferon-driven inflammation. These findings highlight the potential for mitochondrial-targeted therapies in JDM management and emphasise the need for further studies to explore their therapeutic value. KEY MESSAGES: What is already known on this topic Juvenile dermatomyositis (JDM) involves interferon-driven inflammation and immune-mediated muscle damage. Mitochondrial abnormalities in blood immune cells persist despite treatment and contribute to disease pathology. What this study adds Mitochondrial dysfunction is present in both muscle fibres and tissue-infiltrating immune cells within JDM muscle. These abnormalities are detectable even in clinically less severe muscle weakness. Degree of mitochondrial abnormality at transcript and protein level may be independent of strength of IFN-driven signal. Mitochondrial dysregulation detected at transcriptional level correlates with abnormal transcription of muscle (sarcomere) and the subcellular peroxisome organelle. How this study might affect research, practice, or policy Targeting mitochondrial dysfunction could enhance treatment outcomes for JDM, especially in patients whose disease is refractory to current therapies. Insights from this study support the development of stratification tools to detect aspects of pathology which are not tightly correlated with IFN-driven pathology.
Open AccessSpatial transcriptomic analysis of muscle biopsy from treatment-naive juvenile dermatomyositis patients reveals mitochondrial abnormalities despite disease-related interferon driven signature
Objectives: This study aimed to investigate the spatial transcriptomic landscape of muscle tissue from treatment-naïve juvenile dermatomyositis (JDM) patients in comparison to healthy paediatric muscle tissue. Methods: Muscle biopsies from three JDM patients and three age-matched controls were analysed using the Nanostring GeoMx® Digital Spatial Profiler. Regions of interest were selected based on muscle fibres without immune cells, immune cell infiltration and CD68+ macrophage enrichment. Differential gene expression, pathway analysis and pathways clustering analysis were conducted. Key findings were validated in 19 cases of JDM using immunohistochemistry and chemical stains, and a bulk RNAseq dataset of four cases of JDM. Results: JDM muscle tissues exhibited significant interferon pathway activation and mitochondrial dysfunction compared to controls. A 15-gene interferon signature was significantly elevated in JDM muscle and macrophage-enriched regions, correlating with clinical weakness. In contrast, mitochondrial dysregulation, characterized by downregulated respiratory chain pathways, was present regardless of interferon activity or muscle strength. The interferon-driven and mitochondrial signatures were replicated in an independent RNAseq dataset from JDM muscle; lack of association between interferon signature and mitochondrial dysregulation was validated in 19 cases by conventional staining methods. Clustering analysis revealed distinct transcriptomic profiles between JDM and control tissues, as well as between JDM patients with varying clinical phenotypes. Conclusions: This study highlights mitochondrial dysfunction as a consistent pathological feature in JDM muscle, which may be independent of interferon-driven inflammation. These findings highlight the potential for mitochondrial-targeted therapies in JDM management and emphasise the need for further studies to explore their therapeutic value. KEY MESSAGES: What is already known on this topic Juvenile dermatomyositis (JDM) involves interferon-driven inflammation and immune-mediated muscle damage. Mitochondrial abnormalities in blood immune cells persist despite treatment and contribute to disease pathology. What this study adds Mitochondrial dysfunction is present in both muscle fibres and tissue-infiltrating immune cells within JDM muscle. These abnormalities are detectable even in clinically less severe muscle weakness. Degree of mitochondrial abnormality at transcript and protein level may be independent of strength of IFN-driven signal. Mitochondrial dysregulation detected at transcriptional level correlates with abnormal transcription of muscle (sarcomere) and the subcellular peroxisome organelle. How this study might affect research, practice, or policy Targeting mitochondrial dysfunction could enhance treatment outcomes for JDM, especially in patients whose disease is refractory to current therapies. Insights from this study support the development of stratification tools to detect aspects of pathology which are not tightly correlated with IFN-driven pathology.
- Open Access
Paneth Cells Are a Constitutive Source of IL-10 in Mouse Small Intestinal Organoids
The healthy gut masks a dynamic balance between pro- and anti-inflammatory activities, largely due to microbial factors in the lumen. IL-10 is vital among the anti-inflammatory mediators, yet confirming constitutive versus stimulated secretion in any cell type is difficult due to the cellular complexity in the gut. Seeking to determine whether intestinal epithelial cells are programmed to constitutively make IL-10, we confirmed that IL-10 mRNA was present in enteroids from C57BL/6 mice and IL-10 protein was co-localized with a Paneth cell marker but not with markers for goblet or tuft cells. Paneth cells positive for IL-10 also possessed apical and basal IL-10RA, while cells negative for IL-10 had only basal IL-10RA, suggesting a possible autocrine role for IL-10. Indeed, Paneth cells in IL-10 gene knockout (IL-10KO) enteroids possessed lower levels of anti-microbial protein mRNAs, which could not be restored by adding IL-10. Enteroids passaged onto Transwell® filters to form monolayers were treated with IL-10 and STAT3 phosphorylation was measured. Apically applied IL-10 resulted in a stronger STAT3 signal than basally applied cytokine. Our results indicate that a subpopulation of Paneth cells constitutively secrete IL-10 apically, which binds apical IL-10RA, impacting the expression of anti-microbial proteins unique to Paneth cells.
Open AccessPaneth Cells Are a Constitutive Source of IL-10 in Mouse Small Intestinal Organoids
The healthy gut masks a dynamic balance between pro- and anti-inflammatory activities, largely due to microbial factors in the lumen. IL-10 is vital among the anti-inflammatory mediators, yet confirming constitutive versus stimulated secretion in any cell type is difficult due to the cellular complexity in the gut. Seeking to determine whether intestinal epithelial cells are programmed to constitutively make IL-10, we confirmed that IL-10 mRNA was present in enteroids from C57BL/6 mice and IL-10 protein was co-localized with a Paneth cell marker but not with markers for goblet or tuft cells. Paneth cells positive for IL-10 also possessed apical and basal IL-10RA, while cells negative for IL-10 had only basal IL-10RA, suggesting a possible autocrine role for IL-10. Indeed, Paneth cells in IL-10 gene knockout (IL-10KO) enteroids possessed lower levels of anti-microbial protein mRNAs, which could not be restored by adding IL-10. Enteroids passaged onto Transwell® filters to form monolayers were treated with IL-10 and STAT3 phosphorylation was measured. Apically applied IL-10 resulted in a stronger STAT3 signal than basally applied cytokine. Our results indicate that a subpopulation of Paneth cells constitutively secrete IL-10 apically, which binds apical IL-10RA, impacting the expression of anti-microbial proteins unique to Paneth cells.
- Open Access
- 20 November 2024
- Published by MDPI AG in Preprints.org
Paneth Cells are a Constitutive Source of IL-10 in Mouse Small Intestinal Organoids
The healthy gut masks a dynamic balance between pro- and anti-inflammatory activities, largely due to microbial factors in the lumen. IL-10 is vital among the anti-inflammatory mediators yet confirming constitutive versus stimulated secretion in any cell type is difficult due to the cellular complexity in the gut. Seeking to determine whether intestinal epithelial cells are programmed to constitutively make IL-10, we confirmed that IL-10 mRNA was present in enteroids from C57BL/6 mice and co-localized with a Paneth cell marker but not with markers for goblet or tuft cells. Paneth cells positive for IL-10 also possessed apical and basal IL-10RA while cells negative for IL-10 had only basal IL-10RA, suggesting a possible autocrine role for IL-10. Indeed, Paneth cells in IL-10 gene knockout (IL-10KO) enteroids possessed lower levels of anti-microbial protein mRNAs which could not be restored by adding IL-10. Enteroids passaged onto Transwell® filters to form monolayers were treated with IL-10 and STAT3 phosphorylation was measured. Apically applied IL-10 resulted in a stronger STAT3 signal than basally applied cytokine. Our results indicate that a subpopulation of Paneth cells constitutively secrete IL-10 apically, which binds apical IL-10RA, impacting the expression of anti-microbial proteins unique to Paneth cells.
- 20 November 2024
- Published by MDPI AG in Preprints.org
Open AccessPaneth Cells are a Constitutive Source of IL-10 in Mouse Small Intestinal Organoids
The healthy gut masks a dynamic balance between pro- and anti-inflammatory activities, largely due to microbial factors in the lumen. IL-10 is vital among the anti-inflammatory mediators yet confirming constitutive versus stimulated secretion in any cell type is difficult due to the cellular complexity in the gut. Seeking to determine whether intestinal epithelial cells are programmed to constitutively make IL-10, we confirmed that IL-10 mRNA was present in enteroids from C57BL/6 mice and co-localized with a Paneth cell marker but not with markers for goblet or tuft cells. Paneth cells positive for IL-10 also possessed apical and basal IL-10RA while cells negative for IL-10 had only basal IL-10RA, suggesting a possible autocrine role for IL-10. Indeed, Paneth cells in IL-10 gene knockout (IL-10KO) enteroids possessed lower levels of anti-microbial protein mRNAs which could not be restored by adding IL-10. Enteroids passaged onto Transwell® filters to form monolayers were treated with IL-10 and STAT3 phosphorylation was measured. Apically applied IL-10 resulted in a stronger STAT3 signal than basally applied cytokine. Our results indicate that a subpopulation of Paneth cells constitutively secrete IL-10 apically, which binds apical IL-10RA, impacting the expression of anti-microbial proteins unique to Paneth cells.
- Open Access
- 28 July 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (7) , 1-19
Peroxisomal cholesterol metabolism regulates yap-signaling, which maintains intestinal epithelial barrier function and is altered in Crohn’s disease
Intestinal epithelial cells line the luminal surface to establish the intestinal barrier, where the cells play essential roles in the digestion of food, absorption of nutrients and water, protection from microbial infections, and maintaining symbiotic interactions with the commensal microbial populations. Maintaining and coordinating all these functions requires tight regulatory signaling, which is essential for intestinal homeostasis and organismal health. Dysfunction of intestinal epithelial cells, indeed, is linked to gastrointestinal disorders such as irritable bowel syndrome, inflammatory bowel disease, and gluten-related enteropathies. Emerging evidence suggests that peroxisome metabolic functions are crucial in maintaining intestinal epithelial cell functions and intestinal epithelium regeneration and, therefore, homeostasis. Here, we investigated the molecular mechanisms by which peroxisome metabolism impacts enteric health using the fruit fly Drosophila melanogaster and murine model organisms and clinical samples. We show that peroxisomes control cellular cholesterol, which in turn regulates the conserved yes-associated protein-signaling and contributes to intestinal epithelial structure and epithelial barrier function. Moreover, analysis of intestinal organoid cultures derived from biopsies of patients affected by Crohn’s Disease revealed that the dysregulation of peroxisome number, excessive cellular cholesterol, and inhibition of Yap-signaling are markers of disease and could be novel diagnostic and/or therapeutic targets for treating Crohn’s Disease. Our studies provided mechanistic insights on peroxisomal signaling in intestinal epithelial cell functions and identified cholesterol as a novel metabolic regulator of yes-associated protein-signaling in tissue homeostasis.
- 28 July 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (7) , 1-19
Open AccessPeroxisomal cholesterol metabolism regulates yap-signaling, which maintains intestinal epithelial barrier function and is altered in Crohn’s disease
Intestinal epithelial cells line the luminal surface to establish the intestinal barrier, where the cells play essential roles in the digestion of food, absorption of nutrients and water, protection from microbial infections, and maintaining symbiotic interactions with the commensal microbial populations. Maintaining and coordinating all these functions requires tight regulatory signaling, which is essential for intestinal homeostasis and organismal health. Dysfunction of intestinal epithelial cells, indeed, is linked to gastrointestinal disorders such as irritable bowel syndrome, inflammatory bowel disease, and gluten-related enteropathies. Emerging evidence suggests that peroxisome metabolic functions are crucial in maintaining intestinal epithelial cell functions and intestinal epithelium regeneration and, therefore, homeostasis. Here, we investigated the molecular mechanisms by which peroxisome metabolism impacts enteric health using the fruit fly Drosophila melanogaster and murine model organisms and clinical samples. We show that peroxisomes control cellular cholesterol, which in turn regulates the conserved yes-associated protein-signaling and contributes to intestinal epithelial structure and epithelial barrier function. Moreover, analysis of intestinal organoid cultures derived from biopsies of patients affected by Crohn’s Disease revealed that the dysregulation of peroxisome number, excessive cellular cholesterol, and inhibition of Yap-signaling are markers of disease and could be novel diagnostic and/or therapeutic targets for treating Crohn’s Disease. Our studies provided mechanistic insights on peroxisomal signaling in intestinal epithelial cell functions and identified cholesterol as a novel metabolic regulator of yes-associated protein-signaling in tissue homeostasis.
- Open Access
- 18 March 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (10) , e281-e284
TIF1-gamma IgG2 isotype is not associated with malignancy in juvenile dermatomyositis patients
Huong D Nguyen, Fabienne Jouen, Benoit Déchelotte, Nadège Cordel, Cyril Gitiaux, Christine Bodemer, Pierre Quatier, Alexandre Belot, Kathryn O’Brien, Dario Canc
- 18 March 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (10) , e281-e284
Open AccessTIF1-gamma IgG2 isotype is not associated with malignancy in juvenile dermatomyositis patients
Huong D Nguyen, Fabienne Jouen, Benoit Déchelotte, Nadège Cordel, Cyril Gitiaux, Christine Bodemer, Pierre Quatier, Alexandre Belot, Kathryn O’Brien, Dario Canc
- Open Access
- 28 September 2022
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 6 (Supplement)
OA29 Blotting-based assays under-detected TIF1-gamma and NXP2 autoantibodies compared to immunoprecipitation in Juvenile Dermatomyositis cohorts
Introduction/Background: The rare heterogenous autoimmune disease Juvenile Dermatomyositis (JDM) relies on prognostic tools including myositis specific antibodies (MSA) and myositis associated antibodies (MAA) to guide early treatment and reduce the risks of poor outcome. However, there is an emerging concern regarding the inter-assay validity due to the current lack of a standardised protocol for MSA/MAA screening across healthcare centres. Among available MSA/MAA screening assays, most laboratories prefer using immunoblot over immunoprecipitation, due to its practicality and lower cost. Notably, blotting-based assays were reported to have reduced specificity at detecting certain MSA/MAA subgroups. Description/Method: A total of 472 JDM patients recruited via UK Juvenile Dermatomyositis Cohort and Biomarker Study (JDCBS) were included in this study. For immunoprecipitation cohort, the sera of 383 JDM-diagnosed patients were determined at the University of Bath using radio-labelled protein immunoprecipitation, and 140kDa bands were confirmed with ELISA for NXP2 or MDA5. For immunoblot cohort (n = 89), MSA/MAA results were obtained from the patients’ records at the centre of care. The immunoprecipitation group and immunoblot group were investigated for the frequency of each autoantibody subgroup within each cohort. The objective was to determine the sensitivity of each assay in detecting myositis relevant antibodies (MSA/MAA) in the context of JDM. Discussion/Results: Overall, the majority of patients were female, and self-identified as white. Specifically, in immunoprecipitation cohort, 70.9% of the patients were female, while 77.1% of the patients self-identified as white. In the immunoblot cohort, 72.7% of the patient were female, while 65.9% self-identified as white. Regarding MSA/MAA status in each cohort, 225 out of 383 (58%) immunoprecipitation samples were positive for at least 1 myositis relevant autoantibody (MSA/MAA). In the immunoblot cohort the proportion was 53% (47 out of 89 samples). Despite the similar gender and ethnicity distribution, the frequencies of autoantibody subgroups varied between two cohorts. In descending order, the 3 most common MSAs detected by immunoprecipitation group were anti-TIF1γ (18.1%), anti-NXP2 (15.8%) and anti-MDA5 (5.9%). On the contrary, anti-MDA5 (15.5%) was the most prevalent autoantibody detected by immunoblot, followed by anti-TIF1γ (11.3%) and anti-NXP2 (9.3%), respectively. The prevalence of more than one myositis relevant autoantibodies detected in a patient was rare in both cohorts. Specifically, when excluding anti-Ro52, a MAA that is not detected with immunoprecipitation, 2.2% of the total patients in immunoblot cohort had more than 1 MSA/MAA. This rate is lower in immunoprecipitation cohort, as only 0.5% of the patients in this cohort were determined to be positive for more than one autoantibody subgroup. When accounting for anti-Ro52 in immunoblot cohort, 7 out of 8 anti-Ro52 positive patients were also positive for anti-MDA5, making up 7.9% of immunoblot cohort. Key learning points/Conclusion: The variance between autoantibody frequencies detected by each method suggested that immunoprecipitation and immunoblot assays do not perform equally for all MSA and MAA. The lower detection of anti-TIF1γ in immunoblot is consistent with previous reports. Additionally, a potential reduction of sensitivity in anti-NXP2 detection using immunoblot is observed for the first time. Higher rate of anti-MDA5 in immunoblot cohort might reflect the earlier pre-treatment samples compared to the samples tested in immunoprecipitation cohort, as the titre of anti-MDA5 was reported to decrease with treatment. As MSA/MAA status are interpreted by clinicians to classify JDM patients into homogenous subgroups for more focused treatment plans, the reliability of autoantibody screening process is an issue of interest. Further investigations are necessary to characterise the sensitivity and specificity of each method.
- 28 September 2022
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 6 (Supplement)
Open AccessOA29 Blotting-based assays under-detected TIF1-gamma and NXP2 autoantibodies compared to immunoprecipitation in Juvenile Dermatomyositis cohorts
Introduction/Background: The rare heterogenous autoimmune disease Juvenile Dermatomyositis (JDM) relies on prognostic tools including myositis specific antibodies (MSA) and myositis associated antibodies (MAA) to guide early treatment and reduce the risks of poor outcome. However, there is an emerging concern regarding the inter-assay validity due to the current lack of a standardised protocol for MSA/MAA screening across healthcare centres. Among available MSA/MAA screening assays, most laboratories prefer using immunoblot over immunoprecipitation, due to its practicality and lower cost. Notably, blotting-based assays were reported to have reduced specificity at detecting certain MSA/MAA subgroups. Description/Method: A total of 472 JDM patients recruited via UK Juvenile Dermatomyositis Cohort and Biomarker Study (JDCBS) were included in this study. For immunoprecipitation cohort, the sera of 383 JDM-diagnosed patients were determined at the University of Bath using radio-labelled protein immunoprecipitation, and 140kDa bands were confirmed with ELISA for NXP2 or MDA5. For immunoblot cohort (n = 89), MSA/MAA results were obtained from the patients’ records at the centre of care. The immunoprecipitation group and immunoblot group were investigated for the frequency of each autoantibody subgroup within each cohort. The objective was to determine the sensitivity of each assay in detecting myositis relevant antibodies (MSA/MAA) in the context of JDM. Discussion/Results: Overall, the majority of patients were female, and self-identified as white. Specifically, in immunoprecipitation cohort, 70.9% of the patients were female, while 77.1% of the patients self-identified as white. In the immunoblot cohort, 72.7% of the patient were female, while 65.9% self-identified as white. Regarding MSA/MAA status in each cohort, 225 out of 383 (58%) immunoprecipitation samples were positive for at least 1 myositis relevant autoantibody (MSA/MAA). In the immunoblot cohort the proportion was 53% (47 out of 89 samples). Despite the similar gender and ethnicity distribution, the frequencies of autoantibody subgroups varied between two cohorts. In descending order, the 3 most common MSAs detected by immunoprecipitation group were anti-TIF1γ (18.1%), anti-NXP2 (15.8%) and anti-MDA5 (5.9%). On the contrary, anti-MDA5 (15.5%) was the most prevalent autoantibody detected by immunoblot, followed by anti-TIF1γ (11.3%) and anti-NXP2 (9.3%), respectively. The prevalence of more than one myositis relevant autoantibodies detected in a patient was rare in both cohorts. Specifically, when excluding anti-Ro52, a MAA that is not detected with immunoprecipitation, 2.2% of the total patients in immunoblot cohort had more than 1 MSA/MAA. This rate is lower in immunoprecipitation cohort, as only 0.5% of the patients in this cohort were determined to be positive for more than one autoantibody subgroup. When accounting for anti-Ro52 in immunoblot cohort, 7 out of 8 anti-Ro52 positive patients were also positive for anti-MDA5, making up 7.9% of immunoblot cohort. Key learning points/Conclusion: The variance between autoantibody frequencies detected by each method suggested that immunoprecipitation and immunoblot assays do not perform equally for all MSA and MAA. The lower detection of anti-TIF1γ in immunoblot is consistent with previous reports. Additionally, a potential reduction of sensitivity in anti-NXP2 detection using immunoblot is observed for the first time. Higher rate of anti-MDA5 in immunoblot cohort might reflect the earlier pre-treatment samples compared to the samples tested in immunoprecipitation cohort, as the titre of anti-MDA5 was reported to decrease with treatment. As MSA/MAA status are interpreted by clinicians to classify JDM patients into homogenous subgroups for more focused treatment plans, the reliability of autoantibody screening process is an issue of interest. Further investigations are necessary to characterise the sensitivity and specificity of each method.